Christopher J Sneeringer

Title: Innovations of Christopher J Sneeringer

Introduction

Christopher J Sneeringer is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of cancer treatment through his innovative research and patents. With a total of four patents to his name, Sneeringer is recognized for his work in developing inhibitors for human EZH2.

Latest Patents

One of Sneeringer's latest patents focuses on inhibitors of human EZH2 and methods of use thereof. This invention relates to the inhibition of both wild-type and certain mutant forms of human histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex. This complex catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). The invention is particularly significant as it selectively inhibits the mutant form of EZH2, thereby preventing the trimethylation of H3-K27, which is associated with various cancers. The methods developed can be utilized to treat cancers such as follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Additionally, the patent provides methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and for determining responsiveness to an EZH2 inhibitor in a subject.

Career Highlights

Christopher J Sneeringer is currently employed at Epizyme, Inc., where he continues to advance his research in cancer therapeutics. His work has been instrumental in the development of targeted therapies that aim to improve patient outcomes.

Collaborations

Sneeringer has collaborated with notable colleagues, including Robert A Copeland and Victoria M Richon, who have also contributed to the field of cancer research.

Conclusion

Christopher J Sneeringer's innovative work in developing EZH2 inhibitors showcases his commitment to advancing cancer treatment. His contributions are paving the way for new therapeutic options for patients battling various forms of cancer.